- Home
- VCYT
VCYT
Veracyte Inc.
as 07-23-2025 4:00pm EST
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.1B | IPO Year: | 2013 |
| Target Price: | $39.89 | AVG Volume (30 days): | 971.8K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.73 - $47.32 | Next Earning Date: | 08-06-2025 |
| Revenue: | $463,393,000 | Revenue Growth: | 23.42% |
| Revenue Growth (this year): | 12.55% | Revenue Growth (next year): | 9.79% |
Stock Insider Trading Activity of Veracyte Inc. (VCYT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bhanji Muna | VCYT | Director | Jun 13 '25 | Sell | $26.67 | 4,589 | $122,366.60 | 29,989 | |
| Leite John | VCYT | Chief Commercial Officer-CLIA | Jun 4 '25 | Sell | $27.20 | 2,809 | $76,409.86 | 94,540 |
Latest Veracyte Inc. News
VCYT Breaking Stock News: Dive into VCYT Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Veracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last year
Zacks
2 months ago
Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?
Insider Monkey
2 months ago
Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO
Business Wire
2 months ago
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
Business Wire
2 months ago
Veracyte to Participate in Upcoming Investor Conferences
Zacks
2 months ago
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
Simply Wall St.
2 months ago
Veracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting Next
Zacks
2 months ago
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
Compare VCYT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.